ArticleDermatology and therapy2026
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRisankizumab (RZB) is an approved injectable IL-23 inhibitor with demonstrated high levels of skin clearance, and icotrokinra (ICO) is an oral IL-23 receptor blocker recently approved for the treatment of moderate-to-severe plaque psoriasis. In the absence of head-to-head trials, this study uses matching-adjusted indirect comparison (MAIC) to compare RZB with ICO in the treatment of adult patients with moderate-to-severe psoriasis.
methodsIndividual patient data from phase 3 RZB trials and summary data from published ICO phase 3 trials were used in this MAIC through week 52. Risk differences between RZB and ICO placebo-adjusted response rates (anchored) were assessed for ≥ 75%, ≥ 90%, and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90, and PASI 100) and Investigator's Global Assessment (IGA) of 0 and 0/1 (IGA 0 and IGA 0/1) every 4 weeks up to week 16. Risk differences between RZB and ICO unadjusted response rates (unanchored) at weeks 24 and 52, along with confidence intervals and P-values, are also presented.
resultsAt 16 weeks, the PBO-adjusted response rates (RZB versus ICO) were 80.6% versus 61.7%, with a risk difference (RD) of 18.9% (95% CI 11.5, 26.4; P < 0.001) for PASI 75; 71.4% versus 49.9% (RD: 21.5%; 95% CI 15.6, 27.4; P < 0.001) for PASI 90; 42.3% versus 29.4% (RD: 13.0%; 95% CI 7.9, 18.0; P < 0.001) for PASI 100; 77.8% versus 58.4% (RD: 19.4%; 95% CI 12.4, 26.3; P < 0.001) for IGA 0/1; and 41.6% versus 33.9% (RD: 7.7%; 95% CI 2.3, 13.0; P < 0.05) for IGA 0. Results were consistent in the unanchored analysis at weeks 24 and 52.
conclusionIn this analysis, adult patients with moderate-to-severe psoriasis treated with RZB demonstrated greater clinical efficacy as early as week 4 or 8, and through week 52 compared with ICO.
Indexed as
Identifiers
42393457What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.